Non-steroidal anti-inflammatory drugs and melanoma risk: Large dutch population-based case-control study

Journal of Investigative Dermatology

Volumn 129, Issue 11, 2009, Pages 2620-2627

  Joosse, Arjen ^a   Koomen, Elsje R ^a   Casparie, Mariël K ^b   Herings, Ron M C ^c   Guchelaar, Henk Jan ^a   Nijsten, Tamar ^d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Foundation PALGA   (Netherlands)

^c Institute for Drug Outcome Research   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLOFENAC; ACETYLSALICYLIC ACID; CARBASALATE CALCIUM; CELECOXIB; DEXIBUPROFEN; DEXKETOPROFEN; DICLOFENAC; DIFLUNISAL; DIPYRONE; ETORICOXIB; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; SULINDAC; TENOXICAM; TIAPROFENIC ACID; TOLFENAMIC ACID;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MELANOMA; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SEX DIFFERENCE; SYSTEMATIZED NOMENCLATURE OF MEDICINE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; RISK FACTORS; RISK REDUCTION BEHAVIOR; SEX DISTRIBUTION; SKIN NEOPLASMS; YOUNG ADULT;

EID: 70350072659     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.201     Document Type: Article

References (36)

1. Asgari MM, Maruti SS, White E (2008) A large cohort study of nonsteroidal anti-inflammatory drug use and melanoma incidence. J Natl Cancer Inst 100:967-971
2. Bundscherer A, Hafner C, Maisch T, Becker B, Landthaler M, Vogt T (2008) Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines. Oncol Rep 19:547-553
3. Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH et al. (2007) Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29:19-24
4. Chiu LC, Tong KF, Ooi VE (2005) Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells. Biomed Pharmacother 59(Suppl 2):S293-7
5. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE et al. (2005) Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294:47-55 (Pubitemid 41002838)
6. de Vries E, Bray FI, Coebergh JW, Parkin DM (2003) Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in Western Europe and decreases in Scandinavia. Int J Cancer 107:119-126
7. de Vries E, Coebergh JW (2004) Cutaneous malignant melanoma in Europe. Eur J Cancer 40:2355-2366
8. de Vries E, Nijsten TE, Visser O, Bastiaannet E, van Hattem S, Janssen-Heijnen ML et al. (2008) Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol 19:583-589
9. Demierre MF (2006) What about chemoprevention for melanoma? Curr Opin Oncol 18:180-184
10. Denkert C, Kobel M, Berger S, Siegert A, Leclere A, Trefzer U et al. (2001) Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 61:303-308
11. Eigentler TK, Caroli UM, Radny P, Garbe C (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4:748-759
12. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G (2009) Aspirin, salicylates and cancer. Lancet 373:1301-1309
13. Francis SO, Mahlberg MJ, Johnson KR, Ming ME, Dellavalle RP (2006) Melanoma chemoprevention. J Am Acad Dermatol 55:849-861
14. Goulet AC, Einsphar JG, Alberts DS, Beas A, Burk C, Bhattacharyya A et al. (2003) Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression. Cancer Biol Ther 2:713-718
15. Harris RE, Beebe-Donk J, Alshafie GA (2006) Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 6:27
16. Harris RE, Beebe-Donk J, Doss H, Burr Doss D (2005) Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 13:559-583
17. Harris RE, Beebe-Donk J, Namboodiri KK (2001) Inverse association of non-steroidal anti-inflammatory drugs and malignant melanoma among women. Oncol Rep 8:655-657
18. Harris RE, Beebe-Donk J, Schuller HM (2002) Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep 9:693-695
19. Hercberg S, Ezzedine K, Guinot C, Preziosi P, Galan P, Bertrais S et al. (2007) Antioxidant supplementation increases the risk of skin cancers in women but not in men. J Nutr 137:2098-2105
20. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE (2007) A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 99:608-615
21. Koomen ER, Joosse A, Herings RM, Casparie MK, Bergman W, Nijsten T et al. (2007) Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin? Eur J Cancer 43:2580-2589
22. Koomen ER, Joosse A, Herings RM, Casparie MK, Guchelaar HJ, Nijsten T (2009) Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study. Ann Oncol 20:358-364
23. Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED (2006) Long-term adherence with cardiovascular drug regimens. Am Heart J 151:185-191
24. Kuzbicki L, Sarnecka A, Chwirot BW (2006) Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression. Melanoma Res 16:29-36
25. Lasithiotakis K, Leiter U, Meier F, Eigentler T, Metzler G, Moehrle M et al. (2008) Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer 112:1795-1804
26. Lau HS, de Boer A, Beuning KS, Porsius A (1997) Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 50:619-625
27. Lee C, Ramirez JA, Guitart J, Diaz LK (2008) Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression. J Cutan Pathol 35:989-994
28. Levin RI (2005) The puzzle of aspirin and sex. N Engl J Med 352:1366-8
29. Marx J (2001) Cancer research. Anti-inflammatories inhibit cancer growth-but how? Science 291:581-582
30. May RC (2007) Gender, immunity and the regulation of longevity. Bioessays 29:795-802
31. Nettelbeck DM, Rivera AA, Davydova J, Dieckmann D, Yamamoto M, Curiel DT (2003) Cyclooxygenase-2 promoter for tumour-specific targeting of adenoviral vectors to melanoma. Melanoma Res 13: 287-292
32. Perron L, Bairati I, Moore L, Meyer F (2003) Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 106:409-415
33. Ramirez CC, Ma F, Federman DG, Kirsner RS (2005) Use of cyclooxygenase inhibitors and risk of melanoma in high-risk patients. Dermatol Surg 31:748-752
34. Rickles FR, Falanga A (2001) Molecular basis for the relationship between thrombosis and cancer. Thromb Res 102:V215-24
35. Vogt T, McClelland M, Jung B, Popova S, Bogenrieder T, Becker B et al. (2001) Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II. Melanoma Res 11:587-599
36. Xu XC (2002) COX-2 inhibitors in cancer treatment and prevention, a recent development. Anticancer Drugs 13:127-137